Posted inBiotechnology
Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs…
Posted inBiotechnology
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine,…
Posted inBiotechnology
3D Micro-Trench Imaging via Fourier Ptychographic Interferometry
In a major leap forward for microscopic imaging, a team of researchers has unveiled an innovative technique designed to capture…
Posted inBiotechnology
Population Sequencing Reveals EBV DNA Persistence
It looks like your input was cut off mid-sentence. From what you’ve provided, the passage discusses the challenges in resolving…
Posted inBiotechnology
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout
Roche has waved goodbye to a inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid…
Posted inBiotechnology
Next-Token Prediction Powers Large Multimodal Models
In the realm of artificial intelligence, a groundbreaking advance is reshaping how machines comprehend and generate interconnected sensory data. Researchers…
Posted inBiotechnology
Bionano Mapping Reveals Complexities of Chromosomal Duplications
Bionano optical genome mapping has emerged as a revolutionary technique in the realm of genetic research, allowing scientists to visualize…
Posted inBiotechnology
Revolutionizing Cancer Treatment: Precision Exatecan Delivery
In an era where tailored treatments are becoming increasingly vital, the emergence of antibody-drug conjugates (ADCs) has revolutionized the landscape…
Posted inBiotechnology
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance…
Posted inBiotechnology
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
Sanofi is tight-lipped about the future of its underwhelming pact with Denali Therapeutics after the French pharma scrapped what appeared…